Women with a deleterious mutation in the BRCA1/2 genes face a lifetime risk (penetrance) of developing breast cancer (BC) in the order of 55%, compared to 12% in the general population, and of developing ovarian cancer (OC) in the order of 16–59% [1,2,3]. This evidence concerns the gene BRCA1 and ovarian carcinoma.